136 results
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
9 May 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
7:00am
Volunteer hours (U.S.): 37 Amicus-supported community programs: 32 patients /24countries Expanded Access through Feb 2024: Pricing PROMISE
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
of their work and what they contribute to the community Career Development Reimagined performance management process to measure the what and the how, rewarding … Manufacturing and Related GHG Emissions Diversity, Equity, & Inclusion (DEI) 580 Volunteer hours (U.S.): 22 Amicus-supported community programs: 32
8-K
EX-99.2
bt0sxmy
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
S-3ASR
98jlp65slw4 lp3n
8 Nov 23
Automatic shelf registration
5:25pm
8-K
EX-99.2
q91w7
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-10.1
jrh9o41x6wd lkv
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
ehhjg87dyon
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
EX-99.1
xk25so9ppe7w6u
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.1
8qpgg1 e64werdm3awp
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
EX-99.1
rkyg7 y1ch
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.2
5ptr3rc
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
1qlssvl5chom55xp hnx
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-10.1
dj6ab ho4kf8pts9ata
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.2
8enbr9xre8
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
l6952
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm